Drug Insights

A Complete Guide to Searching Estradiol on Synapse

7 March 2024
2 min read

Estradiol (E2), a predominant female sex hormone and a member of the estrogen family, is responsible for regulating the menstrual and estrous cycles. It plays a pivotal role in orchestrating the development of female secondary sexual characteristics such as breast growth, widening of the hips, and a characteristic fat distribution pattern, as well as the development and sustenance of female reproductive tissues such as the mammary glands, uterus, and vagina. Apart from these crucial functions, E2 exerts significant effects on various other tissues in the body, including the liver, bone, fat, skin, and the brain. Estradiol activates both subtypes of the estrogen receptor (ERα and ERβ), is considered a potent agonist of these nuclear steroid hormone receptors. The hormone has multiple clinical applications, such as treating menopause symptoms, preventing osteoporosis in menopausal women, and treating low estrogen levels in women with ovarian failure. Moreover, it is also indicated in the treatment of certain types of breast and prostate cancer, which highlights its versatility and clinical significance. Interestingly, E2 is available in a diverse range of forms including oral tablets, topical gels or patches, vaginal creams, and injections, which provide ample options for individuals to choose from, based on their unique and specific requirements, preferences, and medical history. Click on the image below to begin the exploration journey of Estradiol through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

First Patient Treated in IPH6501 Trial for Relapsed/Refractory B-Cell NHL
Latest Hotspot
3 min read
First Patient Treated in IPH6501 Trial for Relapsed/Refractory B-Cell NHL
7 March 2024
Inborn Therapeutics: Initial Participant Treated in Early-to-Mid Stage Trial of IPH6501 for Recurrent or Resistant B-Cell Non-Hodgkin Lymphoma.
Read →
Using Synapse for Your Sulfamethoxazole Research: An Easy Guide
Drug Insights
2 min read
Using Synapse for Your Sulfamethoxazole Research: An Easy Guide
7 March 2024
Sulfamethoxazole was first approved in 1965 by FDA , it was first marketed by Roche and sold under the trade name Gantanol® in the US.
Read →
Promising Early Results for BI-1206 in Chinese Non-Hodgkin's Lymphoma Study by CASI Pharma
Latest Hotspot
3 min read
Promising Early Results for BI-1206 in Chinese Non-Hodgkin's Lymphoma Study by CASI Pharma
7 March 2024
CASI Pharma Announces Encouraging Early Results for BI-1206 in Managing Persistent Forms of Non-Hodgkin’s Lymphoma in Chinese Study.
Read →
Accessing Remdesivir Information on Synapse: A Step-by-Step Approach
Drug Insights
2 min read
Accessing Remdesivir Information on Synapse: A Step-by-Step Approach
7 March 2024
Remdesivir,also known by its trade name VEKLURY®,is a RNA-dependent RNA polymerase (RdRp) inhibitor developed by Gilead Sciences.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.